Effects of the P2RX4 antagonist BR11595 in a guinea pig model of chronic asthma
The P2X4-receptor antagonist BR11595 acutely inhibits AHR, eosinophilia, and Goblet cell hyperplasia after 12 weeks, indicating its potential as a therapeutic target for acute intervention of chronic asthma attacks or exacerbations.
Authors
- Martina Schmidt (ORCID: https://orcid.org/0000-0003-3075-0630)
- Melissa Mol‐van der Veen
- Kimberley S. Belfor
- Loes Kistemaker (ORCID: https://orcid.org/0000-0002-7742-8748)
- Muriel Lizé (ORCID: https://orcid.org/0000-0002-4954-3503)
- Hana Černecká
- Reinoud Gosens (ORCID: https://orcid.org/0000-0002-5595-152X)
- Carolin Ebert
- Theo de Boer (ORCID: https://orcid.org/0000-0003-4678-2493)
- Harm Maarsingh
- Hoeke A. Baarsma (ORCID: https://orcid.org/0000-0002-0792-0374)
- Oliver M. Fischer (ORCID: https://orcid.org/0009-0002-1455-0735)
- Dan Li (ORCID: https://orcid.org/0000-0002-3002-1481)
- Vicky Verschut
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Dialyse Centrum Groningen (NL)
- Bayer (Germany) (DE)
- Palm Beach Atlantic University (US)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1111/bph.70127
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- China Scholarship Council
- Bayer CropScience